Evidence map›Paper›PMID 36826142›Full record

ReviewCurrent oncology (Toronto, Ont.)2023

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.

Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Current status of molecular diagnostics for lung cancer.Exploration of targeted anti-tumor therapy · 2024
    Review
  12. Observational
  13. Article
  14. Article
  15. Cancer cachexia research: coming of age.Translational lung cancer research · 2023
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marco RussanoDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Giulia La CavaDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Alessio CortelliniDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Fabrizio CitarellaDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Alessandro GallettiDivision of Medical Oncology, San Camillo Forlanini Hospital, 00152 Roma, Italy.ORCID 0000-0001-7444-2993
Giuseppina Rita Di FazioDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Valentina SantoDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Leonardo BrunettiDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Alessia VendittelliDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Iacopo FioroniDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Francesco PantanoDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Giuseppe ToniniDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.
Bruno VincenziDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansImmune Checkpoint InhibitorsImmunotherapyBiomarkers, TumorImmune Checkpoint Inhibitorsbiomarkerscombination strategiesimmune checkpoint inhibitorsimmunotherapyliquid biopsynon-small cell lung cancerPD-1/PD-L1 antibodiestissue biomarkers

Identifiers

PMID36826142
PMCPMC9955173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.